Galectin Therapeutics Stock Forecast, Price & News

-0.40 (-9.85 %)
(As of 09/20/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume520,079 shs
Average Volume1.81 million shs
Market Capitalization$212.63 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Galectin Therapeutics logo

About Galectin Therapeutics

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.13 out of 5 stars

Medical Sector

421st out of 1,352 stocks

Pharmaceutical Preparations Industry

206th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

Is Galectin Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Galectin Therapeutics stock.
View analyst ratings for Galectin Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Galectin Therapeutics?

Wall Street analysts have given Galectin Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Galectin Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Galectin Therapeutics?

Galectin Therapeutics saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 3,620,000 shares, an increase of 17.5% from the July 29th total of 3,080,000 shares. Based on an average trading volume of 2,210,000 shares, the days-to-cover ratio is presently 1.6 days. Approximately 8.5% of the company's shares are short sold.
View Galectin Therapeutics' Short Interest

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Galectin Therapeutics

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings results on Monday, August, 16th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.03.
View Galectin Therapeutics' earnings history

How has Galectin Therapeutics' stock been impacted by Coronavirus?

Galectin Therapeutics' stock was trading at $1.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GALT stock has increased by 83.9% and is now trading at $3.66.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GALT?

1 Wall Street analysts have issued twelve-month target prices for Galectin Therapeutics' stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate Galectin Therapeutics' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 282.5% from the stock's current price.
View analysts' price targets for Galectin Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the following people:
  • Joel Lewis, President, Chief Executive Officer & Director
  • Jack W. Callicutt, Chief Financial Officer & Secretary
  • Pol F. Boudes, Chief Medical Officer
  • Ezra R. lowe, Executive Director-Clinical
  • Marla Mills-Wilson, Executive Director-Clinical Operations

Who are some of Galectin Therapeutics' key competitors?

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.36%), Advisor Group Holdings Inc. (2.19%), BlackRock Inc. (1.37%), Millennium Management LLC (0.98%), Geode Capital Management LLC (0.70%) and Renaissance Technologies LLC (0.64%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio and Kevin D Freeman.
View institutional ownership trends for Galectin Therapeutics

Which major investors are selling Galectin Therapeutics stock?

GALT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Bank of America Corp DE, and Wells Fargo & Company MN. Company insiders that have sold Galectin Therapeutics company stock in the last year include Fund LP 10X, and Gilbert F Amelio.
View insider buying and selling activity for Galectin Therapeutics
or view top insider-selling stocks.

Which major investors are buying Galectin Therapeutics stock?

GALT stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Cambridge Investment Research Advisors Inc., Ergoteles LLC, Tibra Equities Europe Ltd, Susquehanna International Group LLP, Renaissance Technologies LLC, Squarepoint Ops LLC, and Advisor Group Holdings Inc..
View insider buying and selling activity for Galectin Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $3.66.

How much money does Galectin Therapeutics make?

Galectin Therapeutics has a market capitalization of $212.63 million. The company earns $-23,470,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Galectin Therapeutics have?

Galectin Therapeutics employs 6 workers across the globe.

What is Galectin Therapeutics' official website?

The official website for Galectin Therapeutics is

Where are Galectin Therapeutics' headquarters?

Galectin Therapeutics is headquartered at 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at (678) 620-3186 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.